- Researchers find that targeting growth-driving cells within tumors, not the fastest-proliferating cells within tumors, may lead to more effective treatments.
- In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers from Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular abnormalities.
- Dana-Farber Cancer Institute is recognized as a Magnet® organization for excellence in nursing and patient care for the third time.
- U.S. News and World Report ranks Dana-Farber/Brigham and Women's Cancer Center the top hospital in New England for the 14th straight year.
- Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.
- Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.
Tags: BasicResearch, LungCancer
- Research led by Bruce Spiegelman, PhD, and colleagues shows that adipsin, a cell signaling protein made by fat cells, plays a critical, previously unsuspected role in stimulating insulin secretion to control blood sugar, and the discovery could have implications for treatment of type 2 diabetes.
- Dana-Farber Cancer Institute is acquiring the Commonwealth Hematology-Oncology (CHO) physician practice and extending its sophisticated cancer care model further into the community, effective July 1, 2014.
- Researchers at Dana-Farber and Brigham and Women's Hospital (BWH) have utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression.
Tags: BasicResearch, MultipleMyeloma
- Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.
Tags: BasicResearch, LungCancer, Immunotherapy
Showing 21-30 of 535 items